According to Ridge Pharmaceutical, it is hoped that the "sister medicine" of the Lianhua Qingjuan capsule/granules will be cultivated into the next large market.
According to the surging news report, the investor relationship campaign record form announced on the afternoon of Tuesday (February 14) of Shijiazhuang Yiling Pharmaceutical Co., Ltd. shows that this year, even Huaqing cough tablets have successfully renewed the country's country.Medical insurance, coupled with the support of the Lianhua brand and the sales channels of Lianhua Qingjuan, the company hopes to cultivate it into the next large market.
Yiling Pharmaceutical said that in response to the systematic study of respiratory diseases such as crown disease, acute bronchitis, and chronic bronchitis, even flower clear cough tablets have formed theoretical, practical, evidence -based scientific researchEvidence chain.Based on the exact efficacy and scientific research support, the drug has been recommended by 28 national and provincial diagnosis and treatment plans, of which 6 national new crown diagnosis and treatment plans are recommended.Directory recommendation.
In the future, the company plans to continue to conduct a number of clinical trials around the product to create more evidence chains for product promotion.
According to the introduction of Yiling Pharmaceutical, Lianhua Cough Tablets are innovative Chinese medicines that guide the treatment of exogenous cough based on the theory of linked disease.The product has the characteristics of "phlegm and cough".Generating, reducing sputum viscosity, and promoting sputum excretion can effectively solve the infectious or infectious diseases of the respiratory system. In the virus or bacterial infection caused by virus or bacterial infection, the phlegm stagnation can be blocked.Or aggravated clinical problems.At the same time, it also has protective airway mucosa, relieves air tract spasm, improves airway resistance, and reduces lung damage and significant antitussive effects caused by repeated occurrence of airway inflammation.
According to the company's official website, Yiling Pharmaceutical has been listed in the field of cold respiratory systems.It played a positive role in prevention and control.Lianhua Qingya Tablets obtained drug registration approval not only enriched the clinical medication in the field of disease treatment, and further enriched the company's product echelon in the field of respiratory system.
As a "sister medicine" as the Lianhua Qing Plague capsule/granules, even the cough tablets are expected to have a good development prospect in this cough field, which will help improve the company's products in the field of respiratory diseases.The market competitiveness is expected to become the company's new business growth point in the future.
Established in 1992, Ling Pharmaceutical was listed in A shares in July 2011. The main business is the research and development, production and sales of patent innovation Chinese medicine. Among themThe second enters the coronary diagnosis and treatment plan has attracted attention.Yiling Pharmaceutical closed on Tuesday and reported to 29.64 yuan (RMB, about S $ 5.77) per share, up 1.02%.
